Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 6/2013

01-12-2013 | Original Paper

The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies

Authors: Jen Kruger, Alan Brennan

Published in: The European Journal of Health Economics | Issue 6/2013

Login to get access

Abstract

Aims

To identify cost-of-illness studies of Type 1 diabetes mellitus (Type 1 DM) in the United Kingdom (UK) and review this literature to estimate the current cost of Type 1 DM to the UK National Health Service.

Methods

Bibliographic databases and grey literature were searched systematically to identify all published and unpublished reporting of the costs of Type 1 DM in the UK. Studies were excluded if they did not present cost information from the UK or did not disaggregate information by diabetes type. Three grey literature sources and 11 published studies were identified for inclusion in the literature review.

Results

The included studies and reports covered topics including the overall cost of Type 1 DM, costs of individual diabetic complications and costs of specific interventions for Type 1 DM. The most recent published estimate of the cost of Type 1 DM was over 15 years old, and although this estimate has been inflated to current prices the estimate is not adjusted for changes to treatment pathways over this period and is therefore not considered an accurate estimate of current costs of Type 1 DM.

Conclusions

There is no recently published estimate of the cost of Type 1 DM in the UK; therefore, it is recommended that an up-to-date national, comprehensive cost-of-illness study should be conducted. Recommendations for the format of this study are made, including extending the scope to cover recent treatment developments and resource use where diabetes is a subsidiary diagnosis.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Ettaro, L., Songer, T., Zhang, P., Engelgau, M.: Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 22, 149–164 (2004)PubMedCrossRef
5.
Currie, C., Peters, J.: Trends in the volume and cost of prescribing for diabetes. Br. J. Med. Econ. 8, 1–9 (1995)
6.
Donnan, P.T., Leese, G.P., Morris, A.D.: Hospitalizations for people With Type 1 and Type 2 diabetes compared with the nondiabetic population of Tayside, Scotland. Diabet. Care. 23, 1774–1779 (2000)CrossRef
7.
8.
Gray, A., Fenn, P., McGuire, A.: The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet. Med. 12, 1068–1076 (1995)PubMedCrossRef
9.
Drummond, M., Sculpher, M., Torrance, G., O’Brien, B., Stoddart, G.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Wanless, D.: Securing our future health: taking a long-term view. HM Treasury, London (2002)
25.
Pagano, E., Brunetti, M., Tediosi, F., Garattini, L.: Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics 15, 583–595 (1999)PubMedCrossRef
26.
27.
Personal Social Services Research Unit: Unit Costs of Health and Social Care 2010. Compiled by Lesley Curtis, ed. University of Kent, Canterbury (2010)
28.
National Institute for Health and Clinical Excellence: Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus: review of technology appraisal guidance 57 (2008)
29.
30.
Currie, C., Peters, J.: Costs of insulin-dependent diabetes mellitus. Diabet. Med. 13, 684–685 (1996)PubMedCrossRef
31.
Currie, C.J., Poole, C.D., Woehl, A., Morgan, C.L., Cawley, S., Rousculp, M.D., et al.: The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet. Med. 24, 187–194 (2007)PubMedCrossRef
32.
Hammer, M., Lammert, M., Mejias, S.M., Kern, W., Frier, B.M., Hammer, M., et al.: Costs of managing severe hypoglycaemia in three European countries. J. Med. Econ. 12, 281–290 (2009)PubMedCrossRef
33.
Leese, G.P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., et al.: Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26, 1176–1180 (2003)PubMedCrossRef
34.
Gordois, A., Scuffham, P., Shearer, A., Oglesby, A., Gordois, A., Scuffham, P., et al.: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J. Diabet. Complicat. 18, 18–26 (2004)CrossRef
35.
Evans, J.M., MacDonald, T.M., Leese, G.P., Ruta, D.A., Morris, A.D.: Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care 23, 770–774 (2000)PubMedCrossRef
36.
Poole, C., Tetlow, T., McEwan, P., Holmes, P., Currie, C.J.: The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr. Med. Res. Opin. 23, S41–S48 (2007)CrossRef
37.
Colquitt, J.L., Green, C., Sidhu, M.K., Hartwell, D., Waugh, N.: Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol. Assess. 8, iii-171 (2004)
38.
Feltbower, R.G., Campbell, F.M., Bodansky, H.J., Stephenson, C.R., McKinney, P.A.: Insulin pump therapy in childhood diabetes-cost implications for Primary Care Trusts. Diabet. Med. 23, 86–89 (2006)PubMedCrossRef
39.
40.
de Lusignan, S., Khunti, K., Belsey, J., Hattersley, A., van Vlymen, J., Gallagher, H., et al.: A method of identifying and correcting miscoding, misclassification and misdiagnosis in diabetes: a pilot and validation study of routinely collected data. Diabet. Med. 27, 203–209 (2010)PubMedCrossRef
41.
Gray, J., Ekins, M., Scammell, A., Carroll, K., Majeed, A.: Workload implications of identifying patients with ischaemic heart disease in primary care: population-based study. J. Public Health Med. 25, 223–227 (2003)PubMedCrossRef
42.
de Lusignan, S., Gallagher, H., Chan, T., Thomas, N., Van Vlymen, J., Nation, M.: The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care. Implement. Sci. 4, 39 (2009)PubMedCrossRef
43.
44.
45.
National Institute for Health and Clinical Excellence: Guidance on the use of patient-education models for diabetes (2003)
46.
Simell, T.T., Sintonen, H., Hahl, J., Simell, O.G.: Costs of insulin-dependent diabetes mellitus. Pharmacoeconomics 9, 24–38 (1996)PubMedCrossRef
47.
48.
49.
Metadata
Title
The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies
Authors
Jen Kruger
Alan Brennan
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 6/2013
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-012-0433-4

Other articles of this Issue 6/2013

The European Journal of Health Economics 6/2013 Go to the issue

Original Paper

Managing for efficiency in health care: the case of Greek public hospitals

Original Paper

TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial

Original Paper

How efficient are Greek hospitals? A case study using a double bootstrap DEA approach

Original Paper

Long-term health investment when people underestimate their adaptation to old age-related health problems

Original Paper

The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice

Editorial

Channeling health economics research initiatives to improve decision-making processes in the EU